| In millions, except per share items | Dec-31-20 | Sep-30-20 | Jun-05-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Jun-05-19 |
| | 10-K | 10-Q | 8-K | 10-Q | 10-K | 10-Q | 10-Q | 8-K |
| Revenue | | 3,110.1 | | 3,127.9 | 3,066.3 | 2,995.7 | 2,932.6 | |
| Revenue growth | | 3.8% | | 8.2% | 6.8% | -24.1% | -13.4% | |
| Operating expenses: | | | | | | | | |
| Cost of revenue | | | | | | | | |
| Selling, general and administrative expenses | | 435.8 | | 404.8 | 394.9 | 387.8 | 384.8 | |
| Transaction-related costs | | -43.2 | | 2.4 | 1.8 | 3.7 | | |
| Depreciation and amortization expense | | 127.5 | | 119.6 | 114.9 | 113.5 | 112.6 | |
| Loss on disposal of fixed assets | | 0.4 | | 1.0 | 1.1 | 1.0 | 0.7 | |
| Income from operations | | 332.4 | | 348.4 | 363.9 | 359.3 | 302.3 | |
| Operating margin | | 10.7% | | 11.1% | 11.9% | 12.0% | 10.3% | |
| Interest expense, net | | -50.3 | | -53.1 | -52.0 | -51.4 | -52.8 | |
| Foreign currency losses, net | | -16.2 | | -0.5 | -2.3 | 2.2 | -5.0 | |
| Other (expense) income, net | | 0.2 | | 0.3 | 0.2 | -0.2 | -0.3 | |
| Income before income taxes and equity in income of unconsolidated joint ventures | | 264.1 | | 65.9 | 65.9 | 82.9 | 170.8 | |
| Provision for income taxes | | 43.5 | | 51.5 | 62.8 | 68.2 | 85.0 | |
| Tax rate | | 16.5% | | 78.3% | 95.4% | 82.2% | 49.8% | |
| Net income | | 206.7 | | 239.5 | 243.1 | 198.4 | 158.3 | |
| Net income attributable to noncontrolling interest | | | | | | | -0.1 | |
| Net income attributable to PRA Health Sciences, Inc. | | 220.6 | | 239.6 | 243.0 | 239.6 | 158.2 | |
| |
| Net income per share attributable to common stockholders: | | | | | | | | |
| Basic (in dollars per share) | | $3.50 | | $3.75 | $3.78 | $3.70 | $2.44 | |
| Diluted (in dollars per share) | | $3.41 | | $3.65 | $3.68 | $3.61 | $2.38 | |
| |
| Weighted average common shares outstanding: | | | | | | | | |
| Basic (in shares) | | 63.5 | | 64.4 | 64.9 | 64.9 | 64.7 | |
| Diluted (in shares) | | 64.9 | | 65.8 | 66.5 | 66.5 | 66.6 | |